Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 2.3% – Should You Sell?

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) dropped 2.3% during mid-day trading on Monday . The stock traded as low as $2.88 and last traded at $2.92. 915,349 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 2,297,648 shares. The stock had previously closed at $2.99.

Analyst Upgrades and Downgrades

Separately, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $12.62.

Perspective Therapeutics Trading Down 0.3%

The firm has a 50-day moving average of $3.36 and a 200 day moving average of $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. As a group, research analysts predict that Perspective Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics in the 4th quarter worth $28,000. Russell Investments Group Ltd. increased its position in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the last quarter. nVerses Capital LLC bought a new position in Perspective Therapeutics in the fourth quarter valued at about $31,000. AXQ Capital LP lifted its holdings in Perspective Therapeutics by 24.2% in the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares during the period. Finally, Engineers Gate Manager LP purchased a new position in Perspective Therapeutics in the fourth quarter worth about $35,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.